ArticleDrug metabolism and disposition: the biological fate of chemicals2025
Fibroblast growth factor 15 overexpression and combined peroxisome proliferator-activated receptor α activation attenuates metabolic dysfunction-associated steatohepatitis progression in mice.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unlocking the Hepatoprotective Potential of Urolithin A in High-Fat Diet-Induced MASLD: Integrated Role of Oxidative Stress, Inflammation, FXR/PPAR-α, and Fibrotic Pathway.Cell biochemistry and function · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is increasing worldwide along with the obesity epidemic. However, there are limited treatments. Fibroblast growth factor (FGF)19 and its mouse ortholog FGF15, act as hormones to repress bile acid synthesis and increase energy expenditure. Activation of peroxisome proliferator-activated receptor (PPAR)α increases fatty acid oxidation in hepatocytes. However, a combined role of FGF19/15 with activation of PPARα in the treatment of MASH is unknown. Wild-type and Fgf15 transgenic (Fgf15 Tg) mice were fed a high-fat diet (HFD) to induce MASH, then a PPARα agonist was subsequently administered to a subcohort of HFD groups to study the synergistic effect of Fgf15 overexpression and PPARα activation. HFD feeding diminished glucose tolerance and increased liver fat accumulation in both wild-type and Fgf15 Tg mice. However, Fgf15 Tg mice demonstrated resistance to weight gain, displayed improved glucose tolerance, and attenuated liver steatosis. Fgf15 overexpression alone reduced liver injury and the expression of genes involved in inflammation and fibrosis. The activation of PPARα, both individually and in conjunction with FGF15 overexpression, led to weight loss and reduced liver steatosis. However, the combined approach with PPARα activation and FGF15 overexpression resulted in an increase in liver injury and upregulation of gene expression associated with inflammation and fibrosis. In summary, Overexpression of FGF15 alone, with or without a combined activation of PPARα, effectively reduces hepatic steatosis. However, the combined treatment leads to increased oxidative stress and ductular reactions, indicating a complex interplay in the pathogenesis of MASH. SIGNIFICANCE STATEMENT: Fibroblast growth factor (FGF)15 overexpression and peroxisome proliferator-activated receptor (PPAR)α activation ameliorates high-fat diet-induced hepatic steatosis. Combined PPARα activation and FGF15 overexpression exacerbated high-fat diet-induced liver injury and inflammation. Overexpression of FGF15 alone or combination with PPARα activation induced antioxidant response and ductular reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.